Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

Posted byZacks Equity Research Leave a comment on Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

The FDA grants accelerated nod to Seagen (SGEN) and Genmab’s Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease…

Leave a comment

Your email address will not be published. Required fields are marked *